MMP9 and metabolic dysfunction-associated steatotic liver disease: The results of the current study identified seven target genes of dehydrovomifoliol in NAFLD treatment, namely E2F1, MERTK, SOX17, MMP9, SULT2A1, VEGFA, and BLVRA.